The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Frusemid     4-chloro-2-(2- furylmethylamino)-5...

Synonyms: Errolon, Frusemide, Furantral, Fursemide, Furanthril, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of furosemide

 

Psychiatry related information on furosemide

 

High impact information on furosemide

  • Vacuolar H(+)-ATPases are expressed in the plasma membrane in the kidney almost along the entire length of the nephron with apical and/or basolateral localization patterns [11].
  • These go through the intricate process of mesenchyme-to-epithelium transition by which epithelial cell polarization is initiated, and they continue to differentiate into the highly specialized epithelial cell populations of the nephron [12].
  • Because the terminal nephron segments, including the DCT and collecting tubule, reabsorb only a small portion of the filtered Mg (approximately 5%), the loop of Henle plays a major role in the determination of Mg reabsorption, and it is in this segment that the major regulatory factors act to maintain Mg balance [13].
  • Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron [14].
  • The marked increases in glomerular filtration rate and nephron blood flow, which occur at least in some conditions, increase the absolute amount of water and solute delivered to the various nephron segments in ultrafiltrate and peritubular blood [15].
 

Chemical compound and disease context of furosemide

 

Biological context of furosemide

 

Anatomical context of furosemide

  • The apparent marked capacity for compensatory growth in all nephron segments and even in portions of tubular segments in parenchymal renal disease increases the area for transport by tubular epithelia in residual nephrons, as the overall number of nephrons diminishes.. [15].
  • The high deformability of erythrocytes which is essential for their transport through the capillaries depends critically on their discoid shape and on the elasticity of the plasma membrane, which may be determined by interactions of the cytoskeleton, the lipid/protein leaflet and the glycocalyx [25].
  • Thus, Wnt-4 appears to act as an autoinducer of the mesenchyme to epithelial transition that underlies nephron development [21].
  • Images of the intrinsic optical signal acquired during these slice experiments indicated that furosemide coincidentally blocked changes in extracellular space [26].
  • The kidney can be thought of as the pairing of two tubes: an epithelial tube (the nephron), carrying filtered blood and engaged in ion and water transport; and endothelial tubes (the blood vessels), delivering blood and carrying away recovered solute [27].
 

Associations of furosemide with other chemical compounds

  • Treated patients exhibited significant (P less than 0.05) reductions of blood pressure when supine and upright, and of plasma dopamine-beta-hydroxylase activity, and furosemide-stimulated renin activity when upright [20].
  • In a double-blind, randomized, crossover study, we compared the effect of an aerosol of the loop diuretic furosemide with that of a placebo on the early (within 60 minutes) and late (4 to 12 hours) asthmatic responses to a specific inhaled allergen [28].
  • Both hydrochlorothiazide and furosemide significantly reduced blood pressure (BP) during three months of therapy [29].
  • Using a targeted proteomics approach, we screened renal protein extracts with rabbit polyclonal antibodies directed to each of the major Na transporters expressed along the nephron to determine whether escape from aldosterone-mediated Na retention is associated with decreased abundance of one or more of renal Na transporters [30].
  • Angiotensin II binding sites in individual segments of the rat nephron [31].
 

Gene context of furosemide

  • Pharmacologic inhibition of AngII prevented TGF-alpha and TACE accumulation as well as renal lesions after nephron reduction [32].
  • While CFTR is expressed along the entire nephron, its function in renal tubule epithelial cells remains unclear, as no specific renal phenotype has been identified in cystic fibrosis [33].
  • Thus, the two AVP receptor subtypes are distributed differently along the nephron, and these mRNAs are regulated differently in the dehydrated state [34].
  • While macro- and microscopic kidney development appear to proceed normally in mice that lack Foxi1, electron microscopy reveals an altered ultrastructure of cells lining the distal nephron [35].
  • We showed previously that AP-1 complexes are activated during the proliferative response that parallels the development of renal lesions after nephron reduction, but little is known about the specific role of individual Jun/Fos components in the deterioration process [36].
 

Analytical, diagnostic and therapeutic context of furosemide

  • These data show that human D is catabolized by the kidney via glomerular filtration and reabsorption by the proximal nephron [37].
  • To assess the renal functional adaptation to reduced excretory capacity, we studied whole kidney and single nephron function in anesthetized volume-replete rabbits after unilateral (left kidney) nephrectomy (UNX), ureteral obstruction (UO), or ureteroperitoneostomy (UP) [38].
  • Acute papillectomy or furosemide perfusion was performed to interrupt distal tubular fluid flow past the macula densa, thus minimizing tubuloglomerular feedback-dependent influences on afferent arteriolar function [39].
  • Micropuncture during the nonhypertensive period revealed increases in afferent (65%) and efferent (82%) arteriolar resistances, thereby reducing nephron plasma flow rate [40].
  • HEK/EP1 [Ca2+]i responses were observed mainly in preparations from rabbits on a low-salt diet and were completely inhibited by either a selective COX-2 inhibitor or an EP1 antagonist, and also by 100 microM luminal furosemide [41].

References

  1. Fluid secretion in the nephron: Relation to renal failure. Grantham, J.J. Physiol. Rev. (1976) [Pubmed]
  2. Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. Reilly, R.F., Ellison, D.H. Physiol. Rev. (2000) [Pubmed]
  3. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Karet, F.E., Finberg, K.E., Nelson, R.D., Nayir, A., Mocan, H., Sanjad, S.A., Rodriguez-Soriano, J., Santos, F., Cremers, C.W., Di Pietro, A., Hoffbrand, B.I., Winiarski, J., Bakkaloglu, A., Ozen, S., Dusunsel, R., Goodyer, P., Hulton, S.A., Wu, D.K., Skvorak, A.B., Morton, C.C., Cunningham, M.J., Jha, V., Lifton, R.P. Nat. Genet. (1999) [Pubmed]
  4. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. Solomon, R., Werner, C., Mann, D., D'Elia, J., Silva, P. N. Engl. J. Med. (1994) [Pubmed]
  5. Promotion of patent ductus arteriosus by furosemide. Cohen, J.I. N. Engl. J. Med. (1983) [Pubmed]
  6. Brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism. Collins, M.A., Zou, J.Y., Neafsey, E.J. FASEB J. (1998) [Pubmed]
  7. Long-term regulation of inner medullary collecting duct urea transport in rat. Kato, A., Naruse, M., Knepper, M.A., Sands, J.M. J. Am. Soc. Nephrol. (1998) [Pubmed]
  8. Psychological and sex features of delayed gut transit in functional gastrointestinal disorders. Bennett, E.J., Evans, P., Scott, A.M., Badcock, C.A., Shuter, B., Höschl, R., Tennant, C.C., Kellow, J.E. Gut (2000) [Pubmed]
  9. Genetic low nephron number hypertension is associated with dysregulation of the hepatic and renal insulin-like growth factor system during nephrogenesis. Rothermund, L., Nierhaus, M., Fialkowski, O., Freese, F., Ibscher, R., Mieschel, S., Kossmehl, P., Grimm, D., Wehland, M., Kreutz, R. J. Hypertens. (2006) [Pubmed]
  10. Loin pain-hematuria syndrome: role for renal autotransplantation. Chin, J.L. J. Urol. (1992) [Pubmed]
  11. Renal vacuolar H+-ATPase. Wagner, C.A., Finberg, K.E., Breton, S., Marshansky, V., Brown, D., Geibel, J.P. Physiol. Rev. (2004) [Pubmed]
  12. Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Horster, M.F., Braun, G.S., Huber, S.M. Physiol. Rev. (1999) [Pubmed]
  13. Renal magnesium handling and its hormonal control. de Rouffignac, C., Quamme, G. Physiol. Rev. (1994) [Pubmed]
  14. Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Greger, R. Physiol. Rev. (1985) [Pubmed]
  15. Functional adaptation to reduction in renal mass. Hayslett, J.P. Physiol. Rev. (1979) [Pubmed]
  16. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. Green, T.P., Thompson, T.R., Johnson, D.E., Lock, J.E. N. Engl. J. Med. (1983) [Pubmed]
  17. Regulation of prostasin by aldosterone in the kidney. Narikiyo, T., Kitamura, K., Adachi, M., Miyoshi, T., Iwashita, K., Shiraishi, N., Nonoguchi, H., Chen, L.M., Chai, K.X., Chao, J., Tomita, K. J. Clin. Invest. (2002) [Pubmed]
  18. Correction of hypokalemia corrects the abnormalities in erythrocyte sodium transport in Bartter's syndrome. Korff, J.M., Siebens, A.W., Gill, J.R. J. Clin. Invest. (1984) [Pubmed]
  19. The effect of indomethacin and other anti-inflammatory drugs on the renin-angiotensin system. Romero, J.C., Dunlap, C.L., Strong, C.G. J. Clin. Invest. (1976) [Pubmed]
  20. Psychotherapeutic control of hypertension. Stone, R.A., DeLeo, J. N. Engl. J. Med. (1976) [Pubmed]
  21. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Stark, K., Vainio, S., Vassileva, G., McMahon, A.P. Nature (1994) [Pubmed]
  22. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Fushimi, K., Uchida, S., Hara, Y., Hirata, Y., Marumo, F., Sasaki, S. Nature (1993) [Pubmed]
  23. Human hypertension caused by mutations in WNK kinases. Wilson, F.H., Disse-Nicodème, S., Choate, K.A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D.V., Lipkin, G.W., Achard, J.M., Feely, M.P., Dussol, B., Berland, Y., Unwin, R.J., Mayan, H., Simon, D.B., Farfel, Z., Jeunemaitre, X., Lifton, R.P. Science (2001) [Pubmed]
  24. Actions of adrenergic and cholinergic drugs on renal tubular cells. Garg, L.C. Pharmacol. Rev. (1992) [Pubmed]
  25. Viscoelastic properties of erythrocyte membranes in high-frequency electric fields. Engelhardt, H., Gaub, H., Sackmann, E. Nature (1984) [Pubmed]
  26. Dissociation of synchronization and excitability in furosemide blockade of epileptiform activity. Hochman, D.W., Baraban, S.C., Owens, J.W., Schwartzkroin, P.A. Science (1995) [Pubmed]
  27. Making a zebrafish kidney: a tale of two tubes. Drummond, I. Trends Cell Biol. (2003) [Pubmed]
  28. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. Bianco, S., Pieroni, M.G., Refini, R.M., Rottoli, L., Sestini, P. N. Engl. J. Med. (1989) [Pubmed]
  29. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. Araoye, M.A., Chang, M.Y., Khatri, I.M., Freis, E.D. JAMA (1978) [Pubmed]
  30. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. Wang, X.Y., Masilamani, S., Nielsen, J., Kwon, T.H., Brooks, H.L., Nielsen, S., Knepper, M.A. J. Clin. Invest. (2001) [Pubmed]
  31. Angiotensin II binding sites in individual segments of the rat nephron. Mujais, S.K., Kauffman, S., Katz, A.I. J. Clin. Invest. (1986) [Pubmed]
  32. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Lautrette, A., Li, S., Alili, R., Sunnarborg, S.W., Burtin, M., Lee, D.C., Friedlander, G., Terzi, F. Nat. Med. (2005) [Pubmed]
  33. CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney. Lu, M., Leng, Q., Egan, M.E., Caplan, M.J., Boulpaep, E.L., Giebisch, G.H., Hebert, S.C. J. Clin. Invest. (2006) [Pubmed]
  34. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. Terada, Y., Tomita, K., Nonoguchi, H., Yang, T., Marumo, F. J. Clin. Invest. (1993) [Pubmed]
  35. Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. Blomqvist, S.R., Vidarsson, H., Fitzgerald, S., Johansson, B.R., Ollerstam, A., Brown, R., Persson, A.E., Bergström G, G., Enerbäck, S. J. Clin. Invest. (2004) [Pubmed]
  36. JunD protects against chronic kidney disease by regulating paracrine mitogens. Pillebout, E., Weitzman, J.B., Burtin, M., Martino, C., Federici, P., Yaniv, M., Friedlander, G., Terzi, F. J. Clin. Invest. (2003) [Pubmed]
  37. Human complement protein D catabolism by the rat kidney. Sanders, P.W., Volanakis, J.E., Rostand, S.G., Galla, J.H. J. Clin. Invest. (1986) [Pubmed]
  38. Early enhancement of fluid transport in rabbit proximal straight tubules after loss of contralateral renal excretory function. Tabei, K., Levenson, D.J., Brenner, B.M. J. Clin. Invest. (1983) [Pubmed]
  39. Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. Inscho, E.W., Cook, A.K., Imig, J.D., Vial, C., Evans, R.J. J. Clin. Invest. (2003) [Pubmed]
  40. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. Badr, K.F., Murray, J.J., Breyer, M.D., Takahashi, K., Inagami, T., Harris, R.C. J. Clin. Invest. (1989) [Pubmed]
  41. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. Peti-Peterdi, J., Komlosi, P., Fuson, A.L., Guan, Y., Schneider, A., Qi, Z., Redha, R., Rosivall, L., Breyer, M.D., Bell, P.D. J. Clin. Invest. (2003) [Pubmed]
 
WikiGenes - Universities